<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We analyzed toxicity and efficacy of second allogeneic hematopoietic stem cell transplantation (HSCT) or donor lymphocyte infusions (DLI) in 66 patients relapsing with <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (n = 15), <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> (n = 5), <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> (n = 14), non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (n = 14), <z:mp ids='MP_0009440'>myeloma</z:mp> (n = 8), <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (n = 8), and metastatic <z:hpo ids='HP_0005584'>renal cell carcinoma</z:hpo> (n = 2) </plain></SENT>
<SENT sid="1" pm="."><plain>Forty-one patients were given second HSCT and 25 DLI </plain></SENT>
<SENT sid="2" pm="."><plain>Sixteen patients (39%) are alive and disease-free after a second HSCT including 13 who had received nonmyeloablative conditioning </plain></SENT>
<SENT sid="3" pm="."><plain>Thirteen patients (52%) are alive after DLI with mainly <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> patients in continuous complete remission </plain></SENT>
<SENT sid="4" pm="."><plain>Relapse after HSCT is still a challenging situation and further studies to improve outcome of these patients are warranted </plain></SENT>
</text></document>